Cataract surgery drug Omidria received a 2-year reinstatement of pass-through status by the CMS, according to an Omeros press release.
The extension goes into effect Oct. 1. Omidria (phenylephrine 1% and ketorolac 0.3% intraocular solution) was one of several drugs used during procedures on Medicare Part B fee-for-service patients to receive an extension of pass-through reimbursement status.
The 2-year extension was passed into law in March as part of the Consolidated Appropriations Act of 2018. It will remain in effect until Oct. 1, 2020, according to the release.
Omidria is the only